Demographic characteristics | |
Number of patients | 3215 |
Women/Men | 2925 (91%)/290 (9%) |
Age at SLE diagnosis, mean ± SD | 37 ± 13 (range, 19–86 years) |
Age at the time of RELESSER-TRANS inclusion, mean ± SD | 48 ± 14 (range, 19–94 years) |
Ethnic groups | Caucasians: 93%/Hispanics: 5.4%/African-Americans: 0.2%/Asians: 0.6%/Others: 0.8% |
Tobacco | Never: 58%/Before: 25%/At the time of RELESSER-TRANS inclusion: 17% |
Clinical manifestations | |
Constitutional symptoms | Fever 3.6%/Weight loss 9.5% |
Cutaneous | 64% |
Arthritis | 78% |
Raynaud’s phenomenon | 35% |
Vasculitis | 10% |
Nephritis | 31% |
Gastrointestinal involvement | 3% |
Hepatitis | 2.8% |
Pericarditis | 15% |
Non-ischemic cardiac disease | 4.5% |
Neuropsychiatric manifestations | 6.5% |
Hematologic | 79% |
Lymphadenopathy/Splenomegaly | 9.7%/2.9% |
Secondary antiphospholipid syndrome | 17% |
SLEDAI score, mean ± SD | 2.62 ± 3.69 |
SDI score, mean ± SD | 1.15 ± 1.68 |
Immunological laboratory* | |
Anti-dsDNA antibody positivity (available data in all patients) | 72% |
Hypocomplementemia (available data in all patients) | 76.5% |
Anti-Sm antibody positivity (available in 3048 patients) | 21% |
Anti-Ro antibody positivity (available in 3109 patients) | 40% |
Anti-La antibody positivity (available in 3108 patients) | 19% |
Anti-RNP antibody positivity (available in 3095 patients) | 25% |
Anticardiolipin antibody positivity [IgM or IgG] (available in 2952 patients) | 20% |
Anti-beta 2 glycoprotein 1 [IgM or IgG] (available in 1918 patients) | 13.5% |
Lupus anticoagulant (available in 2312 patients) | 23% |
Treatments** | |
Corticosteroids | 88% |
<10 mg/daily of prednisone or equivalent | 46.5% |
10–30 mg/daily | 32% |
>30–60 mg/daily | 21.5% |
Antimalarials | 83.5% |
Methotrexate | 17% |
Azathioprine | 31% |
Cyclophosphamide | 20% |
Mycophenolate | 16% |
Intravenous immunoglobulins | 4% |
Plasmapheresis | 1.5% |
Rituximab | 6% |
Antiplatelet therapy | 36% |
Anticoagulants | 14% |